FOR IMMEDIATE RELEASE
- Conference marks ISSCA’s return to Dubai, United Arab Emirates, December 4–5 at the Hyatt Regency Dubai Creek Heights
- Event closes ISSCA’s international conference calendar for the year
- Release quantifies the year’s countries reached and conferences held, with final physician-trained and certification totals confirmed at publication
MIAMI, FL — The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), today announced ISSCA 129, its return to Dubai, United Arab Emirates, December 4–5 at the Hyatt Regency Dubai Creek Heights, closing ISSCA’s international conference calendar for the year.
The Dubai conference caps a year that included ISSCA events across more than a dozen countries — including Paraguay, Pakistan, Portugal, Brazil, the Dominican Republic, Peru, Argentina, Turkey, Mexico, Bolivia, and Colombia — alongside continued growth of its Online Academy and certification programs. Final totals for physicians trained and certifications issued across the year will be confirmed at time of publication.
ISSCA positioned Dubai as a fitting close to the calendar given the UAE’s role as a regional hub connecting Middle Eastern, South Asian, and African physician communities to ISSCA’s education network.
“Closing the year in Dubai lets us look back at a genuinely global conference calendar — Latin America, the Middle East, and everywhere in between,” said David Christensen, Chief Executive Officer and President of Regenerative Medical Technology Group, Inc. “It’s also where we start planning next year’s expansion.”
About Regenerative Medical Technology Group, Inc.
Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG) is an SEC-reporting regenerative medicine company operating through its wholly owned subsidiary Global Stem Cells Group and Global Stem Cells Group’s operating divisions — Cellgenic, the International Society for Stem Cell Application (ISSCA), and Cellular Hope Institute. The Company’s network reaches physicians and patients across more than 30 countries, combining biologics and regenerative-medicine product commercialization, physician education and certification, and physician-directed clinical services. RMTG’s stated mission is to help physicians make the benefits of regenerative medicine available to patients worldwide.
About ISSCA
The International Society for Stem Cell Application (ISSCA), the physician-education division of Global Stem Cells Group and Regenerative Medical Technology Group, Inc. (OTC Markets: RMTG), was founded in 2009 and has trained more than 12,000 physicians across more than 45 countries in regenerative medicine, longevity medicine, and related disciplines through certifications, fellowships, conferences, and online education.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors — including regulatory developments, market acceptance, operational execution, competitive conditions, currency and economic factors, and the Company’s ability to maintain compliance with applicable laws — that could cause actual results to differ materially from those expressed or implied. Words such as “plan,” “forecast,” “anticipate,” “estimate,” “project,” “intend,” “expect,” “should,” “believe,” and similar expressions are intended to identify forward-looking statements. These statements are based on management’s current expectations and are qualified in their entirety by the risks described more fully in the Company’s filings with the U.S. Securities and Exchange Commission. Any forward-looking statement regarding future revenues, market penetration, or operational expansion reflects management’s current belief only and should not be read as a guarantee of any outcome. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
